Combination Therapy against Multidrug Resistance explores the potential of combination therapy as an efficient strategy to combat multi-drug resistance. Multidrug resistance (MDR) occurs when microorganisms such as bacteria, fungi, viruses, and parasites are excessively exposed to antimicrobial drugs such as antibiotics, antifungals, or antivirals, and in response the microorganism undergoes mutations or develops different resistance mechanisms to combat the drug for its survival. MDR is becoming an increasingly serious problem in both developed and developing nations. Bacterial resistance to antibiotics has developed faster than the production of new antibiotics, making bacterial infections increasingly difficult to treat, and the same is true for a variety of other diseases. Combination therapy proves to be a promising strategy as it offers potential benefits such as a broad spectrum of efficacy, greater potency than the drugs used in monotherapy, improved safety and tolerability, and reduction in the number of resistant organisms. This book considers how combination therapy can be applied in multiple situations, including cancer, HIV, tuberculosis, fungal infections, and more. Combination Therapy Against Multidrug Resistance gathers the most relevant information on the prospects of combination therapy as a strategy to combat multridrug resistance and helping to motivate the industrial sector and government agencies to invest more in research and development of this strategy as a weapon to tackle the multidrug resistance problem. It will be useful to academics and researchers involved in the development of new antimicrobial or antiinfective agents and treatment strtategies to combat multidrug resistance. Clinicians and medical nurses working in the field of infection prevention and control (IPC) will also find the book relevant Explores strategic methods with investigation of both short- and long-term goals to combat multidrug resistance Presents a broad scope to understand fully the ways to apply combined therapy to multidrug resistance Provides an overview of combination therapy, but also includes specific cases such as cancer, tuberculosis, HIV and malaria
|Author||: Anh Kim Lam|
|Release Date||: 2020|
|Pages||: 145 pages|
|Author||: Qigui Li,Mark R. Hickman|
|Publisher||: Bentham Science Publishers|
|Release Date||: 2015-06-04|
|ISBN 10||: 1681080540|
|Pages||: 550 pages|
Malaria takes a great toll on human health and well-being, particularly in tropical regions including Sub-Saharan Africa, Southeast Asia, Oceania and parts of the Americas. In recent years, some Plasmodium strains have become increasingly resistant to all classes of conventional antimalarial drugs currently in use. Researchers have, therefore, stepped up efforts to revise atimalarial drug policies, develop new drugs, and implement new strategies to combat this disease. In order to prevent widespread resistance, antimalarial combination therapies (ACTs) have been deployed and a World Antimalarial Resistance Network has been established as a means of anitimalarial drug resistance surveillance. Artemisinin-based combination therapies have proven to be useful as a replacement for standard regimens. Currently, these ACTs successfully cure patients suffering from uncomplicated malaria with superior efficacy and lower toxicity, but there remains a huge challenge (high mortality rate) associated with treatment of severe malaria. Studies of drug disposition and drug efficacy (PK/PD evaluations) are essential to understanding why drugs work as antimalarials as they illustrate issues with drug resistance, drug safety and drug toxicity that are critical to finding the appropriate drug dose for patients. This eBook illustrates how currently available combination antimalarial drugs can be optimized for effective malaria treatment. Chapters in this book explain methods to select combination drugs based on PK/PD evaluations followed by methods o reduce drug toxicity based on these evaluations. The book also summarizes efforts that are being made by the research community to improve ACT. It is, therefore, a handy reference for medical professionals and pharmacologists working on antimalarial drugs.
|Author||: Rebecca Thombre,Kamlesh Jangid,Ravi Shukla,Noton Kumar Dutta|
|Publisher||: Frontiers Media SA|
|Release Date||: 2019-12-19|
|ISBN 10||: 2889632164|
|Pages||: 329 pages|
|Author||: Ghassan M. Matar,Antoine Andremont|
|Publisher||: Frontiers Media SA|
|Release Date||: 2020-02-14|
|ISBN 10||: 2889635155|
|Pages||: 329 pages|
|Author||: Kalpna D. Rakholiya,Mital J. Kaneria,Sumitra V. Chanda|
|Publisher||: Elsevier Inc. Chapters|
|Release Date||: 2013-05-24|
|ISBN 10||: 0128066822|
|Pages||: 296 pages|
Antibiotics are antimicrobial agents that are used to treat infectious diseases. The outbreak of pathogenic antibiotic-resistant strains illustrates our urgent need to search for new alternative sources of treatment. Hence, an attempt has been made in this review to list some plant extracts, essential/volatile oils, and their antimicrobial activity against different microorganisms using different methods, as well as synergistic effects (plant extract-plant extract, plant extract-essential oils, plant extract-conventional antibiotics, phytochemical-antibiotics, and essential oil-essential oil). Plant products and their active constituents are useful in the treatment of infectious diseases caused by multidrug-resistant microbes, food borne diseases caused by food spoiling microbes, and oral pathogens. Products derived from plants have the potential to control microbial growth in diverse situations, and specifically in the treatment of disease. The various aspects of this review may be helpful for the food, cosmetic, and pharmaceutical industries.
Nosocomial and ventilator-associated pneumonia continue to be a major challenge in the management of intensive care patients. In particular, recent developments in microbial resistance are a cause of great concern. Internationally renowned experts provide comprehensive reviews on all the major topics within the field and, in particular, the recent insights into epidemiology, diagnosis and treatment surrounding this field. This Monograph is an essential reference book for both clinicians and researchers alike on this challenging subject.
A comprehensive and cutting-edge review of how practicing physicians can best treat multiple drug resistance in bacterial, viral, protozoal, and helminthic infections. The authors focus on the major hospital and community-acquired pathogens, including S. aureus, S. pneumoniae, Enterococcus, Acinetobacter, and M. tuberculosis, and on the management of such common problems as multiple drug-resistant urinary tract infections and gonorrhea. Among the resistant tropical organisms covered are Salmonella typhi, malaria, and Burkholderia pseudomalei. Resistance to such important antiviral classes as antiretrovirals and anticytomegalovirals is also discussed, as are those measures necessary to prevent the spread of infections patients.
Health Care associated infection (HAI) is an emerging problem worldwide. HAI causes increased morbidity, mortality and average length of stay of the patient in the hospital. HAI also imposes economic burden on the patient, health care set up and also State and National Health care system. It has been estimated that 5 10 % of all hospital admission suffers from HAI even in developed countries. But 30% of HAI are preventable, if we follow the infection control practices properly especially hand hygiene while giving patient care. Hence, in this book importance has been given to Infection Control practices along with emerging trends of HAI due to Pseudomonas aeruginosa, Acinetobacter species etc.
|Author||: Jeanne Marrazzo|
|Publisher||: Elsevier Health Sciences|
|Release Date||: 2013-12-06|
|ISBN 10||: 0323261035|
|Pages||: 153 pages|
This issue of the Infectious Disease Clinics is devoted to the treatment and prevention of the most common STDs – including syphilis, gonorrhea, herpes, and HPV. The articles will discuss the current research in the field such as antimicrobial resistance in treating gonorrhea and the development/trials of a genital herpes vaccine.
Severe Community Acquired Pneumonia is a book in which chapters are authored and the same topics discussed by North American and European experts. This approach provides a unique opportunity to view the different perspectives and points of view on this subject. Severe CAP is a common clinical problem encountered in the ICU setting. This book reviews topics concerning the pathogenesis, diagnosis and management of SCAP. The discussions on the role of alcohol in severe CAP and adjunctive therapies are important topics that further our understanding of this severe respiratory infection.
|Release Date||: 2012-01-09|
|ISBN 10||: 1464950369|
|Pages||: 26 pages|
Stenotrophomonas: Advances in Research and Treatment: 2011 Edition is a ScholarlyPaper™ that delivers timely, authoritative, and intensively focused information about Stenotrophomonas in a compact format. The editors have built Stenotrophomonas: Advances in Research and Treatment: 2011 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Stenotrophomonas in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Stenotrophomonas: Advances in Research and Treatment: 2011 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.
Nanostructures for Antimicrobial Therapy discusses the pros and cons of the use of nanostructured materials in the prevention and eradication of infections, highlighting the efficient microbicidal effect of nanoparticles against antibiotic-resistant pathogens and biofilms. Conventional antibiotics are becoming ineffective towards microorganisms due to their widespread and often inappropriate use. As a result, the development of antibiotic resistance in microorganisms is increasingly being reported. New approaches are needed to confront the rising issues related to infectious diseases. The merging of biomaterials, such as chitosan, carrageenan, gelatin, poly (lactic-co-glycolic acid) with nanotechnology provides a promising platform for antimicrobial therapy as it provides a controlled way to target cells and induce the desired response without the adverse effects common to many traditional treatments. Nanoparticles represent one of the most promising therapeutic treatments to the problem caused by infectious micro-organisms resistant to traditional therapies. This volume discusses this promise in detail, and also discusses what challenges the greater use of nanoparticles might pose to medical professionals. The unique physiochemical properties of nanoparticles, combined with their growth inhibitory capacity against microbes has led to the upsurge in the research on nanoparticles as antimicrobials. The importance of bactericidal nanobiomaterials study will likely increase as development of resistant strains of bacteria against most potent antibiotics continues. Shows how nanoantibiotics can be used to more effectively treat disease Discusses the advantages and issues of a variety of different nanoantibiotics, enabling medics to select which best meets their needs Provides a cogent summary of recent developments in this field, allowing readers to quickly familiarize themselves with this topic area
Pneumonia is an inflammatory disease of the air sacs and surrounding interstitium caused by infectious agents or by endogenous inflammatory tissue disorder termed interstitial pneumonia. The present book covers contemporary topics of community, hospital, and health care-related bacterial and viral pneumonia in the setting of drug resistance, environmental exposures, climate change, hormonal influences, and gender. The topic of interstitial pneumonia is brought under the lens of an immune-related connective tissue disease.
Escherichia coli is a versatile organism and very diverse. Members of this species vary from very pathogenic agents causing different types of diseases including meningitis, gastroenteritis, and septicemia, just to cite a few, to harmless organisms living in the intestines of both humans and animals. E. coli has also been used as a model organism for most bacteria except a few. For this reason, its study provides a huge advantage and can help understand the mechanisms involved in different processes such as pathogenesis, environmental disinfection, nutrient utilization, antibiotic resistance, and diagnostic/detection methods, and these are indeed the topics discussed in this book. The book has been divided into four main sections representing the different facets of E. coli applications, which include disease, biotechnology, environmental engineering and innovative approaches to detection, and lastly its physiology and cell biology. Such processes can be applied to the study of other organisms as well considering the development of diversity; for example, many organisms are capable of horizontal gene transfer, which is capable of increasing the fitness of the bacterial organisms involved and has a great impact on the control of such bacterial organism.
|Release Date||: 2013-06-21|
|ISBN 10||: 1481669893|
|Pages||: 30 pages|
Advances in Cephaloridine Research and Application: 2013 Edition is a ScholarlyPaper™ that delivers timely, authoritative, and intensively focused information about ZZZAdditional Research in a compact format. The editors have built Advances in Cephaloridine Research and Application: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about ZZZAdditional Research in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Advances in Cephaloridine Research and Application: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.
Antibiotic Resistance: Mechanisms and New Antimicrobial Approaches discusses up-to-date knowledge in mechanisms of antibiotic resistance and all recent advances in fighting microbial resistance such as the applications of nanotechnology, plant products, bacteriophages, marine products, algae, insect-derived products, and other alternative methods that can be applied to fight bacterial infections. Understanding fundamental mechanisms of antibiotic resistance is a key step in the discovery of effective methods to cope with resistance. This book also discusses methods used to fight antibiotic-resistant infection based on a deep understanding of the mechanisms involved in the development of the resistance. Discusses methods used to fight antibiotic-resistant infection based on a deep understanding of mechanisms involved in the development of the resistance Provides information on modern methods used to fight antibiotic resistance Covers a wide range of alternative methods to fight bacterial resistance, offering the most complete information available Discusses both newly emerging trends and traditionally applied methods to fight antibiotic resistant infections in light of recent scientific developments Offers the most up-to-date information in fighting antibiotic resistance Includes involvement of contributors all across the world, presenting questions of interest to readers of both developed and developing countries
|Author||: Alimuddin Zumla,Wing-Wai Yew,David S.C. Hui|
|Publisher||: Elsevier Health Sciences|
|Release Date||: 2010-08-31|
|ISBN 10||: 145570038X|
|Pages||: 320 pages|
Respiratory infections are among the most common causes of morbidity and mortality worldwide. These infections present a special challenge to physicians for several reasons, including of the recent disasters caused by severe acute respiratory syndrome (SARS) and bird and swine influenza, the increase in viral and bacterial resistance to currently available anti-microbial drugs, the increased frequency of new viral lung infections in clinical practice, and the worldwide emergence of deadly drug-resistant forms of TB. For these reasons, it is important for infectious disease specialists to have an overview of emerging respiratory infections.
Philip Rosenthal, MD, and a panel of leading malaria experts drawn from academia, the military, and international health organizations survey the latest scientific understanding of antimalarial chemotherapy, emphasizing the molecular mechanisms of resistance and the description of important new targets. Their survey covers the current status of malarial and antimalarial chemotherapy, the relevant biology and biochemistry of malaria parasites, the antimalarial drugs currently available, new chemical approaches to chemotherapy, and possible new targets for chemotherapy. Comprehensive and cutting-edge, Antimalarial Chemotherapy: Mechanisms of Action, Resistance, and New Directions in Drug Discovery clearly delineates all the basic and clinical research now addressing one of the world's major unresolved disease problems, work that is now powerfully driving the rapid pace of antimalarial drug discovery today.